Chemotherapy for oligometastatic prostate cancer.

ABSTRACT:

Purpose of review

To analyze recent trials of upfront chemotherapy to determine how this paradigm can be applied to oligometastatic prostate cancer patients.

Recent findings

Upfront chemotherapy prolongs survival in metastatic prostate cancer, according to the ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer and STAMPEDE docetaxel trials. However, the benefit is driven by the high volume subset and may not apply to low-volume/oligometastatic patients.

Summary

Oligometastatic patients may not all share the same biology. Advanced imaging techniques may help to more accurately identify truly oligometastatic patients. Molecular markers will be necessary to distinguish oligometastatic patients who fare well enough wit

SUBMITTER: Dorff TB 

PROVIDER: S-EPMC9116893 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature